Ridge Augmentation Using Allograft Particles Hydrated with or Without Recombinant Human Platelet-Derived Growth Factor
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring two different methods to help prepare the jawbone for dental implants in patients who have lost bone. Specifically, it will compare using a special type of bone material mixed with either a growth factor or just saline (a saltwater solution) to see which method is more effective in increasing the width of the bone ridge needed for implants. The study is currently looking for participants who are between 18 and 74 years old, speak English, and are patients at the UAB Dental School. To qualify, they must need dental implants to replace missing teeth and have a specific type of bone loss that makes the placement of these implants challenging.
Participants in the trial can expect to receive care that aims to improve their chances of successful dental implant surgery. They will be monitored throughout the process to see how well each method works. It’s important to note that individuals who smoke heavily, have certain medical conditions that could complicate surgery, or have poor oral hygiene may not be eligible to join the study. This trial represents a valuable opportunity to help advance dental care and potentially improve outcomes for future patients needing implants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- • At least 18 years old
- • Must be a patient of the UAB Dental School
- • Able to read and understand informed consent document
- • Need for implants to replace missing tooth or teeth in at least one quadrant of the mouth.
- • Insufficient alveolar ridge width for endosseous implant placement defined as 5mm or less as determined by bone sounding and cone beam computed tomography (CBCT) scan.
- Exclusion Criteria:
- • Non-English speaking
- • Less than 18 years old
- • Smokers/tobacco users (\>10 cigarettes/day)
- • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
- • Patient is a poor compliance risk (i.e., poor oral hygiene, history of alcohol or drug abuse)
- • Vertical loss of bone at edentulous ridge.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
AH
AG
SS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials